Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 1, 2007 (Second Quarter)
Business Overview: Illumina is a leading developer of life science tools for genetic variation analysis. The reporting period is significantly impacted by the January 26, 2007, acquisition of Solexa, Inc., a developer of next-generation sequencing technology, and the February 2007 issuance of $400 million in convertible senior notes.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended July 1, 2007 |
Six Months Ended July 1, 2007 |
Six Months Ended July 2, 2006 |
|---|---|---|---|
| Total Revenue | $84,535 | $156,685 | $70,679 |
| Net Income (Loss) | $9,264 | $(288,812) | $6,664 |
| Diluted EPS | $0.16 | $(5.39) | $0.14 |
| Operating Cash Flow | N/A | $39,126 | $17,263 |
| Cash & Short-term Investments | $343,262 | $343,262 | $130,804 |
| Long-term Debt | $400,000 | $400,000 | $0 |
| Goodwill | $248,778 | $248,778 | $2,125 |
Note: The six-month net loss of $(288.8) million is primarily driven by a one-time non-cash charge of $303.4 million for acquired in-process research and development (IPR&D) related to the Solexa acquisition.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 103% year-over-year for the quarter and 122% for the six-month period. Product revenue grew 104% (quarter) and 127% (six months), driven by higher consumable sales and the introduction of the Illumina Genome Analyzer.
- Profitability Impact: While the company reported a net profit for the quarter ($9.3 million), the six-month period resulted in a significant net loss due to the $303.4 million write-off of Solexa's in-process R&D. Excluding this charge, the company would have reported a net profit.
- Balance Sheet Expansion: Total assets more than doubled from $300.6 million to $773.6 million, largely due to the acquisition of Solexa (adding $248.8 million in goodwill and $23.3 million in intangible assets) and the issuance of $400 million in convertible debt.
- Expense Increases: R&D expenses increased 112% (quarter) and 103% (six months), and SG&A expenses increased 81% (quarter) and 88% (six months), reflecting the integration of Solexa and increased stock-based compensation.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items: The primary unusual item is the $303.4 million non-cash charge for acquired IPR&D from the Solexa merger. Additionally, the company incurred $139.0 million in cash outflows for convertible note hedges and repurchased $251.6 million of its own stock.
- Legal Proceedings (Affymetrix): A jury found Illumina liable for infringing five Affymetrix patents in March 2007, awarding $16.7 million in retroactive damages. The case is ongoing; subsequent phases will determine patent validity and potential damages for post-2005 sales. Illumina has not recorded a reserve for this loss as the outcome is uncertain.
- Outlook: Management expects continued revenue growth driven by new product launches (Human 1M DNA Analysis BeadChip, HumanCNV370-Duo) and the expansion of the installed base. However, margins may fluctuate due to product mix and price competition.
- Liquidity: The company holds $343.3 million in cash and short-term investments. Management believes current resources are sufficient to fund operations for at least the next 12 months.
Key Facts for Investor Verification
- Solexa Integration: Verify the progress of integrating Solexa's sequencing technology and the realization of anticipated synergies, as integration risks are explicitly cited.
- Affymetrix Litigation Outcome: Monitor the second and third phases of the Affymetrix trial regarding patent validity and potential additional damages, which could materially impact future results.
- Convertible Debt Terms: Review the terms of the $400 million 0.625% Convertible Senior Notes due 2014, specifically the conversion triggers and the associated hedge/warrant transactions that may impact future dilution.
- Product Mix Margins: Assess whether the shift toward high-throughput sequencing instruments and consumables sustains the gross margin levels seen in the quarter (64% for products).
- Stock Repurchases: Confirm the remaining capacity under the Rule 10b5-1 trading plan ($25 million remaining as of July 1, 2007) and future capital allocation priorities.